Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$2.11 - $24.30
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$5.52M
Enterprise Value-$4.90M
Total Cash (Recent Filing)$6.91M
Total Debt (Recent Filing)$744.84K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 05, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,123,635
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.22
Price to Sales (P/S)1.41
P/FCF Ratio-9.29
Enterprise Value/Market Cap-0.89
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda0.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4
Revenue Forecast (FY)$35.39M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval — Rivaroxaban CanadaRegulatory approval for a widely used anticoagulant expands the company’s commercial portfolio into Canada, supporting recurring wholesale and pharmacy sales. This reduces product-launch risk, creates a durable revenue stream if launched effectively, and leverages existing distribution channels.
Low Financial LeverageVery low balance-sheet leverage limits interest burden and reduces default risk, giving the company financial flexibility. This permits pursuit of additional approvals or acquisitions without heavy debt service, supporting longer-term execution on commercialization and R&D initiatives.
Asset-light Manufacturing ModelUsing contract manufacturers and channel partners keeps capital expenditure low and enables faster product launches. This asset-light model improves scalability, preserves cash for regulatory/commercial activities, and can sustain gross margins while expanding product breadth over time.
Bears Say
Negative Operating Cash FlowConsistent negative OCF and FCF show operations do not self-fund growth or working capital needs, forcing dependence on external financing. Structural cash burn increases execution risk for product launches and prolongs reliance on capital markets, raising dilution and continuity concerns.
Reliance On Dilutive Equity And WarrantsFrequent equity and warrant actions (discount issuances, adjustable warrants) indicate ongoing capital needs and create persistent dilution risk. This financing approach can erode shareholder value and signal that the business model has not yet generated sustainable internal funding.
Persistent Unprofitable OperationsDespite revenue scale gains, operating losses persist, showing the company has not converted scale into sustainable earnings. Continued negative margins imply structural issues in pricing, cost control, or mix that must be resolved to avoid long-term dependence on external capital.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $2.11 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $5.52M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 63 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on May 14, 2026. The company reported -$2.5 earnings per share for the quarter, the consensus estimate of -$2.5 by $0.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -1.2.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,123,635 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$2.5 in its last earnings report, expectations of -$2.5. Following the earnings report the stock price went down -28.905%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sunshine Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.88%
12-Months-Change
Fundamentals
Return on Equity
-25.58%
Trailing 12-Months
Asset Growth
-4.31%
Trailing 12-Months
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
4.71% Insiders
<0.01% Other Institutional Investors
95.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---